Heterogeneous NLRP3 inflammasome signature in circulating myeloid cells as a biomarker of COVID-19 severity
Tóm tắt
Dysregulated immune response is the key factor leading to unfavorable coronavirus disease 2019 (COVID-19) outcome. Depending on the pathogen-associated molecular pattern, the NLRP3 inflammasome can play a crucial role during innate immunity activation. To date, studies describing the NLRP3 response during severe acute respiratory syndrome coronavirus 2 infection in patients are lacking. We prospectively monitored caspase-1 activation levels in peripheral myeloid cells from healthy donors and patients with mild to critical COVID-19. The caspase-1 activation potential in response to NLRP3 inflammasome stimulation was opposed between nonclassical monocytes and CD66b+CD16dim granulocytes in severe and critical COVID-19 patients. Unexpectedly, the CD66b+CD16dim granulocytes had decreased nigericin-triggered caspase-1 activation potential associated with an increased percentage of NLRP3 inflammasome impaired immature neutrophils and a loss of eosinophils in the blood. In patients who recovered from COVID-19, nigericin-triggered caspase-1 activation potential in CD66b+CD16dim cells was restored and the proportion of immature neutrophils was similar to control. Here, we reveal that NLRP3 inflammasome activation potential differs among myeloid cells and could be used as a biomarker of a COVID-19 patient’s evolution. This assay could be a useful tool to predict patient outcome. This trial was registered at www.clinicaltrials.gov as #NCT04385017.
Tài liệu tham khảo
Li, 2020, Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia, N Engl J Med, 382, 1199, 10.1056/NEJMoa2001316
Jamilloux, 2020, Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions, Autoimmun Rev, 19, 102567, 10.1016/j.autrev.2020.102567
Iwasaki, 2015, Control of adaptive immunity by the innate immune system, Nat Immunol, 16, 343, 10.1038/ni.3123
Medzhitov, 2009, Approaching the asymptote: 20 years later, Immunity, 30, 766, 10.1016/j.immuni.2009.06.004
Takeuchi, 2009, Innate immunity to virus infection, Immunol Rev, 227, 75, 10.1111/j.1600-065X.2008.00737.x
Chow, 2018, RIG-I and other RNA sensors in antiviral immunity, Annu Rev Immunol, 36, 667, 10.1146/annurev-immunol-042617-053309
Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, 395, 497, 10.1016/S0140-6736(20)30183-5
Wen, 2020, Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing [published correction appears in Cell Discov. 2020;6:41], Cell Discov, 6, 31, 10.1038/s41421-020-0168-9
Vabret, 2020, Advancing scientific knowledge in times of pandemics, Nat Rev Immunol, 20, 338, 10.1038/s41577-020-0319-0
Chen, 2019, Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome, Front Microbiol, 10, 50, 10.3389/fmicb.2019.00050
Merad, 2020, Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages [published corrections appear in Nat Rev Immunol. 2020;20(7):448], Nat Rev Immunol, 20, 355, 10.1038/s41577-020-0331-4
Deftereos, 2020, The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): rationale and study design, Hellenic J Cardiol, 61, 42, 10.1016/j.hjc.2020.03.002
Parisi, 2020, Precision medicine in COVID-19: IL-1β a potential target, JACC Basic Transl Sci, 5, 543, 10.1016/j.jacbts.2020.04.006
Cheong, 2020, Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases, Pharmacol Res, 158, 104901, 10.1016/j.phrs.2020.104901
Rodrigues, 2021, Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients, J Exp Med, 218, e20201707, 10.1084/jem.20201707
Ferreira
AC
, SoaresVC, de Azevedo-QuintanilhaIG, et al
SARS-CoV-2 induces inflammasome-dependent pyroptosis and downmodulation of HLA-DR in human monocytes.
www.medrxiv.org/content/10.1101/2020.08.25.20182055v2. Accessed 10 January 2021.
World Health Organization (WHO), 2020, Clinical Management of COVID-19: Interim Guidance
Frat, 2015, High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure, N Engl J Med, 372, 2185, 10.1056/NEJMoa1503326
Martínez-García, 2019, P2X7 receptor induces mitochondrial failure in monocytes and compromises NLRP3 inflammasome activation during sepsis, Nat Commun, 10, 2711, 10.1038/s41467-019-10626-x
Zhao, 2020, Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease, JCI Insight, 5, e139834, 10.1172/jci.insight.139834
Groslambert, 2018, Spotlight on the NLRP3 inflammasome pathway, J Inflamm Res, 11, 359, 10.2147/JIR.S141220
Grieshaber-Bouyer, 2019, Neutrophil heterogeneity as therapeutic opportunity in immune-mediated disease, Front Immunol, 10, 346, 10.3389/fimmu.2019.00346
Cavalli, 2020, Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study, Lancet Rheumatol, 2, e325, 10.1016/S2665-9913(20)30127-2
Pillay, 2010, Functional heterogeneity and differential priming of circulating neutrophils in human experimental endotoxemia, J Leukoc Biol, 88, 211, 10.1189/jlb.1209793
Vitte, 2020, A granulocytic signature identifies COVID-19 and its severity, J Infect Dis, 222, 1985, 10.1093/infdis/jiaa591